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Abstract
A 51-year-old female patient presented with atypical chest pain, laryngo-oesophageal reflux,
increased levels of serum calcium and parathyroid hormone. Ultrasonography showed a
multinodular goiter with a prominent solid nodule in the lower left thyroid lobe and a solid
hypoechoic nodule outside this area.
Tc99m-sestamibi parathyroid scintigraphy was performed to investigate a primary
hyperparathyroidism, revealing an area with increased uptake in the lower left thyroid lobe and
another area with marked uptake lower than this level. Thyroid scintigraphy with 99mTc showed
a cold nodule of the left lower pole. FNA of the thyroid nodule was positive for papillary carcinoma
later verified by postoperative histopathology.
This case underlines the need for a clinical high index of suspicion for synchronous
hyperparathyroidism and thyroid cancer.
Case Report
A 51-year-old female patient presented with symptoms of
atypical chest pain and laryngo-oesophageal reflux. The
patient had a past medical history of nephrolithiasis with
normal renal function. Blood tests revealed increased lev-
els of serum calcium of 12.8 mg/dL (normal, 9.0-10.6 mg/
dL), incrased levels of parathyroid hormone (PTH) at 115
pg/mL (normal, 12-72 pg/mL), and a low serum phos-
phorus level of 2.4 mg/dL (normal, 2.5-4.5 mg/dL), find-
ings suggestive for primary hyperparathyroidism. Free
thyroxine (FT4), triiodothyronine (FT3) and thyroid-
stimulating hormone (TSH) levels were within normal
limits.
Ultrasonography displayed a multinodular goiter (total
thyroid volume was about 43 ml) with a prominent solid
nodule in the lower third of the left lobe of the thyroid
gland and an additional solid hypoechoic nodule outside
the gland but in close relation to the lower pole of the left
lobe of it. Multiple endocrine neoplasia (MEN) syndrome
was excluded since no blood test no abdomen CT gave
evidence of pheochromocytoma existence.
Dual phase 99mTc-sestamibi parathyroid scintigraphy
was performed in order to investigate the etiology of pri-
mary hyperparathyroidism. The early images obtained 15
minute after 20 mCi radiotracer injection, revealed an
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area with increased radioactivity in the left lower thyroid
lobe (Figure 1) and a faint radioactivity lower than this
level. The delayed image obtained 3 hours after injection
showed persistent activity in the left lower thyroid lobe
and more clearly the faint radioactivity lower than the
level of the left thyroid lobe (Figure 2).
Two days later a thyroid scintigraphy with 99mTc was per-
formed for thyroid pathology investigation in which a
cold nodule of the left lower pole was detected (Figure 3).
The patient underwent parathyroidectomy and a total thy-
roidectomy. No palpable cervical lymph nodes were dis-
covered after detailed intraoperative exploration of the
region. Histopathology results revealed parathyroid ade-
noma (1.5 cm greater diameter) in the left lower parathy-
roid gland and coexistent papillary carcinoma of the left
lower lobe of thyroid gland (infiltrating, 2 cm in greater
diameter).
The patient's postoperative course was uneventful, nor-
mocalcemia was achieved immediately after parathyroid-
ectomy, and she was discharged from the hospital on the
third postoperative day. Fifty days later the patient
received 100 mCi 131I to ablate any residual thyroid paren-
chyma followed by treatment with suppressive doses of
thyroxine (T4; 175 mg/day).
Discussion
Primary hyperparathyroidism is a rare condition, however
its incidence presents a noticeable increase over the last
decades [1].
An association between hyperparathyroidism and well-
differentiated thyroid carcinoma has been reported in
many studies. In a retrospective study of 824 patients who
had undergone cervical exploration for hyperparathy-
roidism in which at least a thyroid lobectomy was carried
out, thyroid carcinoma was detected in 18 patients (8.6%)
with primary hyperparathyroidism [2].
Burmeister et al additionally compared the incidence of
thyroid carcinoma among groups of primary, secondary
The early scan (15 minutes after the injection of 20 mCi  99mTc-sestamibi) shows intense focal uptake in the inferior  aspect of the left lobe (white arrow) and faint retention  lower than the left lobe of the thyroid gland Figure 1
The early scan (15 minutes after the injection of 20 
mCi 99mTc-sestamibi) shows intense focal uptake in 
the inferior aspect of the left lobe (white arrow) and 
faint retention lower than the left lobe of the thyroid 
gland.
Delayed image (3 hours later) shows the focal  99mTcSestamibi retention in the left lobe and clearly a syn- chronous faint retention lower than its lower end (white  arrow) Figure 2
Delayed image (3 hours later) shows the focal 
99mTcSestamibi retention in the left lobe and clearly 
a synchronous faint retention lower than its lower 
end (white arrow).
Thyroid scan with 99mTc 2 days later shows a cold nodule in  the lower end of the left lobe (white arrow) Figure 3
Thyroid scan with 99mTc 2 days later shows a cold 
nodule in the lower end of the left lobe (white 
arrow).Cases Journal 2009, 2:9121 http://www.casesjournal.com/content/2/1/9121
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and tertiary hyperparathyroidism patients and found that
the prevalence of thyroid carcinoma in a population of
patients undergoing parathyroidectomy for hyperparathy-
roidism was the same irrespective of whether the patients
had primary, secondary or tertiary hyperparathyroidism
[2]. They concluded that the detection of thyroid carci-
noma at the time of parathyroidectomy is related to risk
factors that are probably not associated with hyperparath-
yroidism. The association between thyroid carcinoma and
hyperparathyroidism may be coincidental.
Diagnostic procedure for the preoperative localization of
a suspected parathyroid adenoma includes a 99mTc sesta-
mibi scintigraphy. Taillefer et al developed a double-
phase imaging procedure with 99mTc sestamibi for the
detection and localization of parathyroid adenomas
based on the fact that 99mTc sestamibi washes out more
rapidly from the thyroid than from abnormal parathyroid
tissue [3]. The above procedure improved surgeons' abil-
ity to localize parathyroid adenomas preoperatively [4].
The presence of a parathyroid adenoma is defined as a
focal area showing increased 99mTc-sestamibi uptake in
projection of the thyroid bed and surrounding areas
including mediastinum. This area presents either a rela-
tively progressive increase over time or a fixed uptake per-
sisted on delayed imaging. On the contrary the uptake in
the surrounding normal thyroid tissue, progressively
decreases over time. The sensitivity of the dual-phase pro-
tocol varies and is influenced by numerous factors. These
factors are related to the tumour such as tumoral tissue
volume, oxyphilic cell content, P-glycoprotein expression,
mitochondrial structure or related to the procedure set up
such as the dose of radiotracer, the timing of imaging after
radiotracer injection, and equipment and settings [5,6].
However, sestamibi scan may be positive in different
benign and malignant thyroid tumours [7]. This is
because the tracer is a lipophilic cationic molecule con-
centrating in cells with different metabolic background
with active or passive transport and intramithochondrial
sequestration. Thus, ambiguous sestamibi scan images
may be observed when parathyroid and thyroid tumours
are associated. This underscores the need of an integrated
approach using the combination of sestamibi scan with
other imaging modalities (e.g. in our case thyroid scintig-
raphy) in the differential diagnosis of selected cases of pri-
mary hyperparathyroidism, especially when associated to
multinodular thyroids, and/or after failure of previous
parathyroid surgery.
Conclusion
Certainly hyperparathyroidism should not be considered
as a high suspicious condition for thyroid cancer; instead,
each patient with hyperparathyroidism should be studied
including as a possible part of a MEN syndrome while the
presence of a non-toxic goiter with suspicious nodule
should also be studied, including a FNAB.
Although the incidence of thyroid malignancy in patients
with hyperparathyroidism is relatively low, delayed thy-
roid clearance of 99mTc sestamibi may need to be inves-
tigated further. This case underlines the need for a clinical
high index of suspicion for synchronous hyperparathy-
roidism and thyroid cancer. Dual-phase 99mTc sestamibi
parathyroid imaging may be useful in detecting thyroid
cancer even along with other diagnostic modalities.
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